Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
02/2010
02/23/2010CA2462289C Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
02/23/2010CA2442974C Use of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of cell proliferation diseases
02/23/2010CA2433021C Isoindole-imide compounds, compositions, and uses thereof
02/23/2010CA2378880C Solutions and methods for inhibition of pain, inflammation and cartilage degradation
02/23/2010CA2335461C Calcium channel blockers
02/23/2010CA2315277C Pharmaceutical compositions containing the long pentraxin ptx3
02/18/2010WO2010019953A1 High concentration local anesthetic formulations for treating non-neuropathic pain
02/18/2010WO2010019646A1 Sphingosine-1-phosphate (s1p) receptor antagonists and methods for use thereof
02/18/2010WO2010019547A1 Imine derivatives as cannabinoid receptor ligands
02/18/2010WO2010019450A2 Synergizing active compounds for treating inflammation and other conditions
02/18/2010WO2010019210A2 Halofuginone analogs for inhibition of trna synthetases and uses thereof
02/18/2010WO2010019034A1 Use of carvacrol for treating inflammatory diseases
02/18/2010WO2010018847A1 Recombinant protein-s composition
02/18/2010WO2010018837A2 Protein cross-linking inhibitor
02/18/2010WO2010018836A2 Polyglutamine aggregation inhibitor
02/18/2010WO2010018134A1 Novel adenine derivatives
02/18/2010WO2010017598A1 Anti-il-12/il-23 antibodies
02/18/2010WO2009154819A3 Treatment of inflammatory conditions and diseases with metal-thiols
02/18/2010WO2009135673A8 Compounds with glycidic structure active in the therapy of systemic and local inflammation
02/18/2010WO2009134962A3 Claudin-4 binding peptides, compositions and methods of use
02/18/2010WO2009132119A3 Substituted oxazolidinones
02/18/2010WO2009129509A3 Methods and compositions for treating post-operative pain comprising a local anesthetic
02/18/2010WO2009129453A3 Clonidine formulation in a polyorthoester carrier
02/18/2010WO2009112488A4 Polyether polyol dendron conjugates with effector molecules for biological targeting
02/18/2010WO2009076602A8 5-alkyl/alkenyl-3-cyanopyridines as kinase inhibitors
02/18/2010US20100041747 Use of certain chemical compounds for the inhibition of the peptidyl-prolyl cis/trans isomerase activity of cyclophilins
02/18/2010US20100041708 N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for it's preparation
02/18/2010US20100041695 Thieno[2,3-b]pyridines as Potassium Channel Inhibitors
02/18/2010US20100041675 treatment of retinopathy comprising administering drugs such as tert-butyl 3-[5-ethyl-6-[4-(5,6,7,8-tetrahydro-(1,8)naphthyridin-2-yl)-piperidin-1-yl]-pyrimidin-4-ylamino]-2-(4-methoxy benzoyl)-propionate
02/18/2010US20100041654 Pyrimidine Derivatives And Their Use As CB2 Modulators
02/18/2010US20100041651 Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
02/18/2010US20100041650 Purine compounds as cannabinoid receptor blockers
02/18/2010US20100041635 Oxindole compounds
02/18/2010US20100041632 Uses of the carboxy-amido-triazole compounds and salts thereof
02/18/2010US20100041624 Buprenorphine formulations for intranasal delivery
02/18/2010US20100041619 Lasonolide compounds as reagents for inducing premature chromosome condensation and methods for treating disorders
02/18/2010US20100041600 Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
02/18/2010US20100041072 Process for identifying a ligand that binds to the nep binding site for the smr1 pentapeptide
02/18/2010US20100040691 Pharmaceutical compositions comprising methotrexate
02/18/2010US20100040678 Organic compounds
02/18/2010US20100040627 Baff receptor (bcma), an immunoregulatory agent
02/18/2010US20100040616 Treatment of autoimmune and inflammatory disease
02/18/2010US20100040607 Combination Therapy with Inhibitors of HMGB and Caspase for the Treatment of Inflammatory Diseases
02/18/2010US20100040604 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
02/18/2010US20100040552 Methods to evaluate glucocorticoid receptor agonists and antagonists for effects on neuron-like cells
02/18/2010US20100040537 antibodies that are wild-type, chimeric, CDR grafted and humanized; disease or disorder in which prostaglandin E2 activity is detrimental, such as cancer, atuoimmune diseases, inflammatory diseases
02/18/2010CA2737219A1 Halofuginone analogs for inhibition of trna synthetases and uses thereof
02/18/2010CA2733970A1 Sphingosine-1-phosphate (s1p) receptor antagonists and methods for use thereof
02/18/2010CA2733750A1 Novel adenine derivatives
02/18/2010CA2733642A1 Anti-il-12/il-23 antibodies
02/18/2010CA2731102A1 Imine derivatives as cannabinoid receptor ligands
02/17/2010EP2154131A1 G protein-coupled receptor inhibitor and pharmaceutical product
02/17/2010EP2153847A1 Gene sensitive to bone/joint disease and use thereof
02/17/2010EP2153833A1 ADP-receptor antagonist for treatment of inflammatory disease
02/17/2010EP2153828A2 Composition for the Transdermal Delivery of Fentanyl
02/17/2010EP2153827A2 Composition for the Transdermal Delivery of Fentanyl
02/17/2010EP2152753A1 Antibodies against ramp3
02/17/2010EP2152369A2 Use of fluoride-containing compounds for diagnostic purposes with the help of imaging processes
02/17/2010EP2152281A2 Composition for treatment of ischemic heart disease, facilitation of blood circulation and angiogenesis, improving skin beauty, improving male sexual function containing ginseng berry extract
02/17/2010EP2152252A2 Selective proteasome inhibitors for treating diabetes
02/17/2010EP1511737B1 Aryloximes
02/17/2010CN101648949A inhibitors of phosphatidylinositol 3-kinase
02/16/2010US7662948 Antisense oligonucleotides against VR1
02/16/2010US7662854 HIF hydroxylase inhibitors
02/16/2010US7662849 N-cyanomethyl-2R-[(benzenesulfonyliminomethyl)amino]-3-(2-difluoromethoxyphenylmethanesulfonyl)-propionamide; treating autoimmune disorders
02/16/2010US7662845 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12
02/16/2010US7662843 Isoxazoline compounds having MIF antagonist activity
02/16/2010US7662836 Indazole having analgesic activity
02/16/2010US7662826 Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
02/16/2010US7662825 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma
02/16/2010US7662817 Psychological disorders; central nervous system disorders; antidepressants; anxiolytic agents; stress reliever; irritable bowel syndrome
02/16/2010US7662807 Sulphonated meso-tetraphenyl chlorins
02/16/2010US7662794 DNA enzyme to inhibit plasminogen activator inhibitor-1
02/16/2010US7662782 Melanocortin 1 receptor selective compounds
02/16/2010US7662633 Method of screening for inhibitors of osteopontin
02/16/2010US7662548 Method of screening for modulators of HIV infection
02/16/2010CA2450922C Piperidines for use as orexin receptor antagonists
02/16/2010CA2429109C Anti-inflammatory agents
02/16/2010CA2407043C Naphthamidine urokinase inhibitors
02/16/2010CA2402436C Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
02/16/2010CA2309154C Substituted porphyrins
02/16/2010CA2308551C Phenanthroline derivatives
02/16/2010CA2220433C Il-6 activity inhibitor
02/11/2010WO2010017545A2 Triazole compounds that modulate hsp90 activity
02/11/2010WO2010017403A2 Therapeutic compositions, devices and methods for observing treated tissues
02/11/2010WO2010017368A2 Methods and compositions for treating anxiety
02/11/2010WO2010017323A1 Novel methylenedioxy phenolic compounds and their use to treat disease
02/11/2010WO2010017103A2 Fully human anti-human nkg2d monoclonal antibodies
02/11/2010WO2010017055A2 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
02/11/2010WO2010017051A1 Novel phenylamino isonicotinamide compounds
02/11/2010WO2010016590A1 Therapeutic or prophylactic agent for generalized pain syndrome
02/11/2010WO2010015929A2 Uses of mesenchymal stem cells
02/11/2010WO2010015874A1 Pharmaceutical uses of lanosta-8,24-dien-3-ols
02/11/2010WO2010015792A1 Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
02/11/2010WO2010015657A2 New alkoxypyrazoles
02/11/2010WO2010015656A2 New alkoxypyrazoles
02/11/2010WO2010015613A1 Organic compounds
02/11/2010WO2010015586A2 2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds
02/11/2010WO2010015585A1 6-benzyl-2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds
02/11/2010WO2010015583A1 Novel diphenyl 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
1 ... 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 ... 1272